Camrelizumab plus apatinib in patients with recurrent or metastatic nasopharyngeal carcinoma failing first-line therapy: An open-label, single-arm, phase II study
机构:[1]Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center,Guangzhou, China[2]Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center,Guangzhou, China[3]Radiotherapy, The First Affiliated Hospital of Kunming MedicalUniversity, Kunming, China昆明医科大学附属第一医院[4]Biostatistics, School of Public Health, Southern MedicalUniversity, Guangzhou, China
第一作者机构:[1]Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center,Guangzhou, China
推荐引用方式(GB/T 7714):
X. Ding,W. Zhang,R. You,et al.Camrelizumab plus apatinib in patients with recurrent or metastatic nasopharyngeal carcinoma failing first-line therapy: An open-label, single-arm, phase II study[J].ANNALS OF ONCOLOGY.2022,33(7):S846-S846.doi:10.1016/j.annonc.2022.07.787.
APA:
X. Ding,W. Zhang,R. You,X. Zou,Z. Wang...&M. Chen.(2022).Camrelizumab plus apatinib in patients with recurrent or metastatic nasopharyngeal carcinoma failing first-line therapy: An open-label, single-arm, phase II study.ANNALS OF ONCOLOGY,33,(7)
MLA:
X. Ding,et al."Camrelizumab plus apatinib in patients with recurrent or metastatic nasopharyngeal carcinoma failing first-line therapy: An open-label, single-arm, phase II study".ANNALS OF ONCOLOGY 33..7(2022):S846-S846